@article{ref1,
title="Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry",
journal="Expert review of neurotherapeutics",
year="2022",
author="Pillai, Manaswini and Erridge, Simon and Bapir, Lara and Nicholas, Martha and Dalavaye, Nishaanth and Holvey, Carl and Coomber, Ross and Barros, Daniela and Bhoskar, Urmila and Mwimba, Gracia and Praveen, Kavita and Symeon, Chris and Sachdeva-Mohan, Simmi and Rucker, James J. and Sodergren, Mikael H.",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="BACKGROUND: The current paucity of clinical evidence limits the use of cannabis-based medicinal products (CBMPs) in post-traumatic stress disorder (PTSD). This study investigates health-related quality of life (HRQoL) changes and adverse events in patients prescribed CBMPs for PTSD. <br><br>METHODS: A case-series of patients from the UK Medical Cannabis Registry was analyzed. HRQoL was assessed at 1-, 3-, and 6-months using validated patient reported outcome measures (PROMs). Adverse events were analyzed according to the Common Terminology Criteria for Adverse Events version 4.0. Statistical significance was defined as p < 0.050. <br><br>RESULTS: Of 162 included patients, 88.89% (n = 144) were current/previous cannabis users. Median daily CBMP dosages were 5.00 (IQR: 0.00-70.00) mg of cannabidiol and 145.00 (IQR: 100.00-200.00) mg of Δ9-tetrahydrocannabinol. Significant improvements were observed in PTSD symptoms, sleep, and anxiety across all follow-up periods (p < 0.050). There were 220 (135.8%) adverse events reported by 33 patients (20.37%), with the majority graded mild or moderate in severity (n = 190, 117.28%). Insomnia and fatigue had the greatest incidence (n = 20, 12.35%). <br><br>CONCLUSIONS: Associated improvements in HRQoL were observed in patients who initiated CBMP therapy. Adverse events analysis suggests acceptability and safety up to 6 months. This study may inform randomized placebo-controlled trials, required to confirm causality and determine optimal dosing.<p /> <p>Language: en</p>",
language="en",
issn="1473-7175",
doi="10.1080/14737175.2022.2155139",
url="http://dx.doi.org/10.1080/14737175.2022.2155139"
}